Press releases

28 Jun 2024

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

26 Jun 2024

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

14 Jun 2024

Acquisition of own shares

13 Jun 2024

New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels

12 Jun 2024

UCB to share first presentations of BIMZELX[®]▼ (bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

10 Jun 2024

Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps

Press releases

Press releases

Search Press releases

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

Acquisition of own shares

New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels

UCB to share first presentations of BIMZELX[®]▼ (bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our 2026...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2025 - Direct access to our latest annual report

UCB Community Health Fund enters a new phase

UCBCares® - Discover what UCBCares® is about and the services they offer

BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study...

Strong Execution Fueling Sustained Company Growth

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment...

Strong Execution Fueling Sustained Company Growth

Innovation and Execution Power UCB’s Success

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

Acquisition of own shares

New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels

UCB to share first presentations of BIMZELX[®]▼ (bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps

Choose a Country